Nice use of sequencing to confirm the connection between the water source and infected individuals AND a great motivation to keep using my water filter when hiking!!!

Great to be invited to talk AACR by Peter Kuhn and AACR President Lillian L. Siu to discuss how we can improve cancer outcomes through intercepting disease with ctDNA based screening assays. Proud to represent industry and specifically Illumina at such an important meeting.

I hope you enjoyed the talk! I enjoyed being able to advocate for screening and, importantly, including all communities in the development, validation, and adoption of existing and emerging tests!

The data we use should represent the full diversity of the human population. With equitable representation in the data, therapies and solutions can be attuned to a broader set of genomes. Let’s get this done!

As a country, we are in such a better place with these state and local public health labs actively participating in pathogen surveillance! Than you for all the hard work during a very challenging time.

Erin - Your reporting has certainly aged well given Moderna AACR presentations on their study results from a personalized melanoma vaccine!

Very cool to think about the impact on human health. Personally, I am celebrating #DNADay23 by using my genome information to stay as healthy as possible while working to ensure many others, from all communities, can benefit from DNA sequencing in times of health and illness.

Congratulations Duncan! Your leadership through the pandemic gave me a front seat perspective on how you apply your deep knowledge of infectious disease, public health, and technology to the benefit of our communities! Great to see you step into this role!

I don’t know, Serafim. While I would not want an EHR-toxic doctor to go head to head vs. a fresh AI-avatar, I still believe in the ability of humans to connect therapeutically through interactions that are not readily captured with DNNs

While a lot of folks don’t want to believe it, TMB provides a way to identify patients who may benefit from I/O therapy. I don’t know how you can say you are “doing everything you can”, stay evidence based, and not know the TMB of an advanced cancer patient. #saveTMB

This is incredibly important work to ensure the benefits of genomics are realized by all AND only the beginning to ensure a truly representational reference genome is available for individuals across the globe. nature.com/articles/s4158…

Great pick for the NIH! I have had the privilege to work closely with Monica over the years. She is a brilliant and thoughtful surgeon-scientist leader that will provide outstanding direction to the NIH. science.org/content/articl…

Dengue & Marburg & SARS, Oh My! As COVID-19 becomes an endemic public health challenge, genomic surveillance will serve as a critical component of a comprehensive global pandemic early warning system. A few thoughts about recent past, present, and future. illumina.com/company/news-c…

Great to see UK's NICE endorse this use of pharmacogenomics for patients with stroke and TIA. 32% of individuals in UK have elevated risk of subsequent stroke when given clopidogrel rather than platelet inhibitors not impacted by CYP2C19. genomeweb.com/molecular-diag…

I think Chris will need your expertise at the site. Perhaps if he offers an awesome sample to sequence AND Giants tickets?

Just completed our educational game - “comprehensive genomic protector” - my score was 140 - struggled with EGFR Exon 20 insertions in lung. Come by our booth at #ASCO2023 and beat my score! (Or learn where you need to read more!)

I'm thrilled about this app on @XPeer5 that is helping address the #genomics education gap! Kudos to my peers Holly Snyder and Maria Martinez-Fresno for their efforts on this much needed resource. illumina.com/company/news-c… #MedGeneEd23

Great to see this legislation re-introduced. While massive clinical studies are ongoing and needed, adoption of MCEDs could decrease cancer mortality by 25%. OMB needs to look budget impact (including savings from earlier detection) not just test cost precisionmedicineonline.com/cancer/senator…

What do you get when you combine 250,000 WGS with 20 years of structured clinical data? You get The Alliance for Genomic Discovery with partners including AbbVie, AstraZeneca, Bayer AG, Merck, NashBio, and Illumina. Welcome to the #genome era! illumina.com/company/news-c…

Our partnership with Pillar Biosciences will combine their targeted panels with Illumina 's NGS and bioinformatics for rapid #genomic profiling of tumors when focused testing is needed. Improving care for patients with advanced and high-risk cancer, together. investor.illumina.com/news/press-rel…